From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Women's Health>
  4. Summary and Comment

Gradual or Cold Turkey: When Stopping HT, Is One Better Than the Other?

Mode of HT discontinuation did not affect likelihood of hot-flash recurrence.

Since the publication of the Women's Health Initiative results (JW Womens Health May 2 2006), hormone therapy (HT) has been recommended only for women who have substantial symptoms at menopause — and then only for as long as necessary to alleviate symptoms. But is HT best discontinued abruptly or by tapering? To address this question, Swedish investigators conducted a multicenter trial of 81 women (median age, 59) who had used HT for 3 to 11 years. More than one third of participants used 1-mg estradiol plus 0.5-mg norethindrone acetate daily, 25% used estradiol plus medroxyprogesterone acetate, and 10% used tibolone or higher daily doses of estradiol.

Women were randomized to stop HT abruptly or to take their usual doses every other day for 4 weeks and then stop. Neither the number nor severity of hot flashes or the health-related quality of life (determined by questionnaire) differed during as long as 12 months of follow-up. Moreover, almost half the women (typically those with more-severe hot flashes) resumed HT by 1 year after discontinuation.

Comment: These data add to the growing body of evidence indicating that whether HT is stopped abruptly or gradually doesn't matter and that some women who experience recurrent severe vasomotor symptoms will restart HT. Whether these data are applicable to U.S. practice is unclear because prescribed estrogen doses in this country are sometimes lower and tibolone is not available. Furthermore, whether these conclusions apply equally to women who are taking HT to treat vasomotor symptoms and those who are using HT for other reasons is unclear.

Robert W. Rebar, MD

Published in Journal Watch Women's Health February 4, 2010

Citation(s):

Lindh-Åstrand L et al. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010 Jan/Feb; 17:72.

Reader Remarks:

Review and add to remarks on this article

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Related Content

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2010. Massachusetts Medical Society. All rights reserved.